We explored the ideal method of establishing subcutaneous, breast, and liver tumor models using the same Walker-256 cells, and investigated the dynamic growth characteristics using 18 F-deoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT), which provides basic information for choosing an experimental animal model.
Background
Cancer is still a worldwide threat to human health. Breast cancer is the leading cause of cancer death among females worldwide and liver cancer is the sixth most common cancer and the third leading cause of cancer-related mortality worldwide [1] . Although surgery, radiotherapy, and chemotherapy are widely used clinically, recurrence or metastasis still happens and leads to poor prognosis. Therefore, more research is needed on suitable animal tumor models to validate the efficacy of radiotherapy and chemotherapy in basic research.
The Walker-256 rat cell line is the pure strain of epithelial cells from this tumor discovered in 1928 by Walker in the breast of a pregnant rat as a mammary carcinosarcoma [2] and been widely used for its high tumorigenicity and invasive growth pattern. Many researches also used Walker-256 cells to induce a bone metastasis model because it can simulate the expansion and invasion of malignant tumors. It has been used to establish a variety of tumor models with Sprague-Dawley (SD) or Wistar rats for oncology research, such as breast cancer [3] , skeletal metastases [4] and liver cancer [5] [6] [7] [8] .
Clinically, early treatment response evaluation can help to adjust the therapeutic schedule. Magnetic resonance imaging (MRI) and computed tomography (CT) can only reflect the tumor size and burden. Currently, positron emission tomography/computed tomography (PET/CT) is a commonly used noninvasive method that provides information on the biological functionality of the tumor based on the uptake of a radiolabeled tracer [9] [10] [11] . Changes in the uptake tracer changing after treatment can be used for early response evaluation and to predict the treatment outcome. In particular, glucose analogue -FLT) is a thymidine analogue, which reflects changes in tumor cell proliferative activity. However, different drugs inhibit tumor growth via various mechanisms at different cell cycle phases, and combination chemotherapy is often used clinically to treat patients with tumors, which leads to complicated changes in tumor DNA synthesis. In this situation, 18 F-FLT uptake cannot adequately reflect tumor cell proliferation [12, 13] . Therefore, 18 F-FDG PET/CT is the most universal means of detection, but there are few published studies about 18 F-FDG PET/CT in the existing models.
Thus, we established subcutaneous, breast, and liver tumor models in rats using the same Walker-256 cells. Consecutive 18 F-FDG PET/CT scans were conducted to observe the dynamic characteristics of tumor growth in vivo. We non-invasively analyzed the metabolic characteristics and built a dynamic growing database of rat tumor models, which can provide the basis for choosing the best animal model for use in experiments.
Material and Methods

Animals and cell line
All the animal care and experimental procedures were conducted in accordance with the guidelines of the Ren Ji Institutional Animal Care and Animal Ethics Committee [14] . Female Sprague-Dawley rats (200-250 g) were purchased from the Ren Ji Hospital Experimental Animal Center, China. Rats were kept under specific pathogen-free conditions at the Laboratory Animal Center. The Walker-256 cell line was obtained from the Laboratory of Translational Medicine of the Jiangsu Province Academy of Traditional Chinese Medicine. The cells were maintained in RPMI-1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% penicillinstreptomycin (Gibco) and were incubated at 37°C with 5% CO 2 and 100% humidity.
Establishment of tumor models
A total of 15 Sprague-Dawley rats (200-250 g) were used to establish subcutaneous tumor (female rats, n = 5), breast tumor (female rats, n = 5) and liver tumor (female rats, n = 5) models Walker-256 cells. Each rat received a subcutaneous injection of Walker-256 cells (0.1 mL, 1×10 ) were first injected subcutaneously into a donor rat. When the tumor diameter reached 6-8 mm, the donor rat was anesthetized with 10% chloral hydrate (3 mL/Kg) and then the tumor was resected and minced into small cubes about 1 mm 3 . The recipient rats were also anesthetized and a 1.5-2 cm long straight lateral rectus incision was made, and the right hepatic lobe was exteriorized on a sterile compress. Then, a tumor block (1 mm 3 ) was embedded in the liver lobe of each recipient rat using a handmade tumor conveyer [7, 8] . After the conveyer was withdrawn, tissue adhesive (3M Vetbond Tissue Adhesive PN) was used to prevent bleeding. Finally, the incision was closed with suture.
F-FDG micro-PET/CT imaging
All animals were fasted 6-8 h before they underwent 18 F-FDG PET/CT. Tumor-bearing rats were anesthetized with isoflurane (2% in oxygen) and placed in prone position. 18 maintained under anesthesia with 2% isoflurane during the scanning. 18 F-FDG micro-PET/CT imaging (Super Nova ® PET/CT, Pingseng, China) was performed, which has a PET spatial resolution of approximately 0.6 mm and a CT voxel size of 0.29 mm. The CT parameters were: x-ray voltage, 60 KV; anode current, and 450 uA. PET images were reconstructed with the orderedsubsets expectation maximization algorithm using 16 subsets and 4 iterations. To estimate the tumor volume of interest, the region of interest covering the tumor was assessed using the 3D segmentation on the PET through Avatar 1.2 software (Pingseng, China). Then, the 3D tumor VOI (VOI 41 ) based on 3D isocontour at 41% of the SUVmax [15] , maximum standardized uptake values (SUV max ), and average standardized uptake values (SUV avg ) were measured. 18 F-FDG PET/CT scans were performed at day 6, day 7, day 8, day 10, day 12, day 14, and day 16 after injection into tumors located subcutaneously and in the breast. For transplanted liver tumors, 18 F-FDG PET/CT scans were performed at day 8, day 9, day 10, day 12, day 14, day 16, and day 18 after inoculation.
Histology analysis
Rats were sacrificed and tumors of each rat were collected on day 16 or day 18 after micro-PET/CT imaging. Tumor tissues were snap-frozen with an optimum-cutting-temperature compound (Sakura, USA) and sectioned into 3 consecutive 5-mm slices. One slice was stained with hematoxylin-eosin (H&E) and one slice was stained with anti-active Ki-67 polyclonal antibodies according to the manufacturer's protocol (Novus, USA). Another slice was immunohistochemically stained used anti-CD31 monoclonal antibody to visualize the blood vessels [16] . The remaining slide was stained with terminal TUNEL (Yeasen, China). The cell nuclei were counterstained with 4',6-diamidino-2-phenylindole) (DAPI, Sigma) [17] . TUNEL-stained slides were visualized under a fluorescence microscope (Zeiss Axio Observer.Z1).
Statistics analysis
Group variation is described as the mean ± standard deviation. The one-way analysis of variance (ANOVA) followed by LSD post hoc test for multiple comparisons was used to compare the differences in tumor VOI and SUVs among the 3 groups (IBM SPSS statistics 22.0, IBM, USA).
Results
Tumor formation and general condition
None of the animals died during inoculation, and successful tumor growth was observed in the postoperative period (Figure 1 ). For subcutaneous and breast tumor models, tumors F-FDG micro-PET/CT imaging on day 8 after inoculation, and the tumors grew locally in the liver as a solitary nodule. Therefore, the tumor formation rates of the 3 different tumor models were all up to 100%. During the first 10 days, there were no obvious changes in diet or activities of rats. Subsequently, the rats showed relative less activity, uneven fur, and less energy. F-FDG uptake areas occurred on day 14 after inoculation in the liver tumor model. The SUV max value of the subcutaneous model increased from 8.15±0.34 (day 5) to 12.38±0.66 (day 10) and then showed an obvious decline to 8.32±0.21 until day 16. For the breast tumor model, the SUV max value climbed to 12.45±0.81 on day 10 and decreased to 8.54±0.46 (day 16). In the liver model, SUV max value showed a remarkable increasing trend from day 8 to day 14 and peaked at 9.97±0.24 on day 14, after which it decreased to 6.84±0.92 on day 18. The SUV max value of tumors in subcutaneous and breast models had a significant difference compared to the liver model (p<0.01). However, we observed no significant differences between subcutaneous and breast tumor models until day 10 (p>0.05) ( Figure 3A) .
The average standard uptake value (SUV avg ) value peaked at 6.83±0.41 at day 8 and then decreased at subsequent observation timepoints ( Figure 3B ). For breast tumors, SUV avg value climbed to 7.10±0.26 on day 8 and decreased during follow-up ( Figure 3B ). The SUV avg value had no significant differences between tumors in subcutaneous and breast models (t=0.90, p=0.37). For the liver tumor model, compared with SUV max value, the maximum of SUV avg value (6.30±0.41) was observed on day 12.
Tumor VOI changes of the 3 tumor location models are shown in Figure 3C . The subcutaneous tumors grew fastest, followed by breast tumors, and the liver tumors grew slowest (p=0.01). The subcutaneous tumor VOI increased from the minimal volume of 89.00±5.61 mm 3 (day 6) to the maximal volume of 1116.93±86.56 mm 3 (day 12). The minimal breast tumor VOI on day 6 was more than 9 times smaller than the maximal size 
Histology analysis
Representative microphotographs of tumors and adjacent normal tissue from rats are shown in Figure 4 . The subcutaneous tumors had extensive necrosis and the nodule consisted of few viable tumor cells, fibroblasts, histiocytes, and lymphoplasmacytes. The viable tumor cells showed a solid growth pattern with a vague nesting formation and the nuclei were large and darkly stained. For the breast tumors, we found that the tumor mass was localized in the breast tissue and small necrotic areas were scattered throughout the tumor. Moreover, the tumor cells demonstrated obviously enlarged nuclei and prominent nucleoli, which had infiltrated mammary ductal tissues. The liver tumors had normal liver tissues and revealed degenerative and necrotic changes, and a small focus of tumor nests was found in the periphery of the tumor.
Representative images Figure 5 show the results of immunohistochemical staining for Ki-67, CD 31, and TUNEL. The viable tumor cells presented a high expression of Ki-67, and there was extensive expression of CD 31 in the periphery of the tumors, indicating a relatively high microvessel density. Similarly, TUNEL-positive apoptotic cells were scattered in the tumors in all 3 tumor models.
Discussion
In this study, we used the Walker-256 cell line to establish subcutaneous, breast, and liver tumor metastasis models in SD rats. We found that the Walker-256 tumor model has advantages of high tumor formation rate, short experimental period, and simple operation. Compared with nude mice, SD rats have a similar architecture of hemodynamics and immune system to humans. Therefore, when compared to humans, there was little difference in invasiveness, angiogenesis, metastasis, drug delivery, and sensitivity to therapeutic agents [18, 19] . 
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In our study, we demonstrated several growth characteristics using the 18 F-FDG PET/CT imaging of these 3 different metastasis tumor models established with Walker-256 cells. Firstly, the results revealed that the tumors in the subcutaneous model grew fastest and had the largest tumor volume. The subcutaneous tumor diameter unexpectedly grew to more than 2 cm at the end of the experiment, probably because the Walker-256 cells were injected in the subcutaneous axillary area, providing larger growth space and better vascularization.
We found that SUV max continued to increase until day 12 in the tumors in the subcutaneous and breast cancer models, but it continued to increase until day 14 in the liver model. There was no significant difference in SUV max between tumors in the subcutaneous and breast models; however, both of them had 563 It is important to realize that the spontaneous decrease of SUVmax and SUVmean can influence the therapeutic evaluation. Therefore, when performing experiments, it is important to select the best duration of therapy, the optimal detection index, and the correct comparison to the control group.
In addition, we successfully established liver transplanted tumor. Traditionally, liver tumor models have been established by injecting tumor cells using a needle. However, this method has certain problems: a) low inoculation rate, and b) inevitable tumor dissemination, allowing the tumor to spill from the puncture channel [20] . To overcome these difficulties, we embedded a small tumor cube (1 mm   3 ) into liver tissues rather than injecting tumor cells, and tissue adhesive was also used to control hemorrhage and peritoneal dissemination of tumor tissue. As a result, we found that the tumor growth was fast and tumor size at each point exhibits only a small variation, which is crucial in evaluating the efficacy of an anti-tumor therapy. Moreover, the spontaneous necrosis is mainly due to the insufficient growth of tumor support tissue. HE staining showed that after necrosis, the tumor cells ruptured and the nuclear structure disappeared; there were large pieces of red dye found, but little lymphocytic infiltration. The results of anti-CD31 staining in our study suggest that Walker-256 transplanted liver tumors are hypervascular, similar to human hepatocellular carcinoma. This characteristic provides a basis for preclinical research on locoregional therapies of liver cancer.
Conclusions
In this study, we successfully established 3 different tumor models (subcutaneous, breast, and liver) with Walker-256 cells in rats. The tumor models showed a high uptake of 18 F-FDG and fast growth, indicating that these tumor models are appropriate for the study of 18 F-FDG PET/CT used to evaluate anti-tumor efficacy.
